Risks associated with vaccinia virus in the laboratory

Virology

Volumn 385, Issue 1, 2009, Pages 1-4

  MacNeil, Adam ^a   Reynolds, Mary G ^a   Damon, Inger K ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Laboratory acquired infection; Orthopoxvirus; Smallpox vaccine; Vaccination; Vaccinia

Indexed keywords

VACCINIA VACCINE;

BIOSAFETY; EXPOSURE; HUMAN; LABORATORY; MONKEYPOX; PATHOGENICITY; PRIORITY JOURNAL; RISK ASSESSMENT; SHORT SURVEY; SMALLPOX; VACCINATION; VACCINIA; VACCINIA VIRUS; VIRUS STRAIN;

HUMANS; LABORATORY INFECTION; LABORATORY PERSONNEL; SMALLPOX VACCINE; VACCINATION; VACCINIA; VACCINIA VIRUS;

ORTHOPOXVIRUS; VACCINIA VIRUS; VARIOLA VIRUS;

EID: 60649107303     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.11.045     Document Type: Short Survey

References (34)

1. Chosewood, C.L., Wilson, D.E. (Eds.), 2007. Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition., 5 ed. US Government Printing Office, Washington D.C.
2. Centers for Disease Control and Prevention (CDC). Laboratory-acquired vaccinia exposures and infections-United States, 2005-2007. MMWR Morb. Mortal. Wkly. Rep. 57 15 (2008) 401-404
3. Amanna I.J., Slifka M.K., and Crotty S. Immunity and immunological memory following smallpox vaccination. Immunol. Rev. 211 (2006) 320-337
4. ATCC; 2008 www.atcc.org.
5. Baggs J., Chen R.T., Damon I.K., Rotz L., Allen C., Fullerton K.E., Casey C., Nordenberg D., and Mootrey G. Safety profile of smallpox vaccine: insights from the laboratory worker smallpox vaccination program. Clin. Infect. Dis. 40 8 (2005) 1133-1140
6. Baxby D. The origins of vaccinia virus. J. Infect. Dis. 136 3 (1977) 453-455
7. Binns M.M., and Smith G.L. Recombinant Poxviruses. (1992), CRC Press, Boca Raton, FL
8. Buller R.M., Smith G.L., Cremer K., Notkins A.L., and Moss B. Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317 6040 (1985) 813-815
9. Casey C.G., Iskander J.K., Roper M.H., Mast E.E., Wen X.J., Torok T.J., Chapman L.E., Swerdlow D.L., Morgan J., Heffelfinger J.D., Vitek C., Reef S.E., Hasbrouck L.M., Damon I., Neff L., Vellozzi C., McCauley M., Strikas R.A., and Mootrey G. Adverse events associated with smallpox vaccination in the United States, January-October 2003. JAMA 294 21 (2005) 2734-2743
10. Casey C., Vellozzi C., Mootrey G.T., Chapman L.E., McCauley M., Roper M.H., Damon I., and Swerdlow D.L. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR Recomm. Rep. 55 RR-1 (2006) 1-16
11. CDC. Notice to readers: newly licensed smallpox vaccine to replace old smallpox vaccine. MMWR 57 8 (2008) 207-208
12. Chakrabarti S., Brechling K., and Moss B. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol. Cell. Biol. 5 12 (1985) 3403-3409
13. Cono J., Casey C.G., and Bell D.M. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm. Rep. 52 RR-4 (2003) 1-28
14. Fine P.E., Jezek Z., Grab B., and Dixon H. The transmission potential of monkeypox virus in human populations. Int. J. Epidemiol. 17 3 (1988) 643-650
15. Greenberg R.N., and Kennedy J.S. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin. Investig. Drugs 17 4 (2008) 555-564
16. Jezek Z., Szczeniowski M., Paluku K.M., and Mutombo M. Human monkeypox: clinical features of 282 patients. J. Infect. Dis. 156 2 (1987) 293-298
17. Jezek Z., Grab B., Paluku K.M., and Szczeniowski M.V. Human monkeypox: disease pattern, incidence and attack rates in a rural area of northern Zaire. Trop. Geogr. Med. 40 2 (1988) 73-83
18. Jones L., Ristow S., Yilma T., and Moss B. Accidental human vaccination with vaccinia virus expressing nucleoprotein gene. Nature 319 6054 (1986) 543
19. Lee M.S., Roos J.M., McGuigan L.C., Smith K.A., Cormier N., Cohen L.K., Roberts B.E., and Payne L.G. Molecular attenuation of vaccinia virus: mutant generation and animal characterization. J. Virol. 66 5 (1992) 2617-2630
20. Lewis F.M., Chernak E., Goldman E., Li Y., Karem K., Damon I.K., Henkel R., Newbern E.C., Ross P., and Johnson C.C. Ocular vaccinia infection in laboratory worker, Philadelphia, 2004. Emerg. Infect. Dis. 12 1 (2006) 134-137
21. Loeb M., Zando I., Orvidas M.C., Bialachowski A., Groves D., and Mahoney J. Laboratory-acquired vaccinia infection. Can. Commun. Dis. Rep. 29 15 (2003) 134-136
22. Mackett M., Smith G.L., and Moss B. General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes. J. Virol. 49 3 (1984) 857-864
23. Mempel M., Isa G., Klugbauer N., Meyer H., Wildi G., Ring J., Hofmann F., and Hofmann H. Laboratory acquired infection with recombinant vaccinia virus containing an immunomodulating construct. J. Invest. Dermatol. 120 3 (2003) 356-358
24. Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc. Natl. Acad. Sci. U. S. A. 93 21 (1996) 11341-11348
25. Moussatche N., Tuyama M., Kato S.E., Castro A.P., Njaine B., Peralta R.H., Peralta J.M., Damaso C.R., and Barroso P.F. Accidental infection of laboratory worker with vaccinia virus. Emerg. Infect. Dis. 9 6 (2003) 724-726
26. Openshaw P.J., Alwan W.H., Cherrie A.H., and Record F.M. Accidental infection of laboratory worker with recombinant vaccinia virus. Lancet 338 8764 (1991) 459
27. Phelps A.L., Gates A.J., Hillier M., Eastaugh L., and Ulaeto D.O. Comparative efficacy of modified vaccinia Ankara (MVA) as a potential replacement smallpox vaccine. Vaccine 25 1 (2007) 34-42
28. Rotz L.D., Dotson D.A., Damon I.K., and Becher J.A. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm. Rep. 50 RR-10 (2001) 1-25 quiz CE1-7
29. Shchelkunov S.N., Marennikova S.S., and Moyer R.W. "Orthopoxviruses Pathogenic for Humans" (2005), Springer, New York
30. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl. Acad. Sci. U. S. A. 89 22 (1992) 10847-10851
31. Tulman E.R., Delhon G., Afonso C.L., Lu Z., Zsak L., Sandybaev N.T., Kerembekova U.Z., Zaitsev V.L., Kutish G.F., and Rock D.L. Genome of horsepox virus. J. Virol. 80 18 (2006) 9244-9258
32. Wharton M., Strikas R.A., Harpaz R., Rotz L.D., Schwartz B., Casey C.G., Pearson M.L., and Anderson L.J. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm. Rep. 52 RR-7 (2003) 1-16
33. Wlodaver C.G., Palumbo G.J., and Waner J.L. Laboratory-acquired vaccinia infection. J. Clin. Virol. 29 3 (2004) 167-170
34. Wokatsch R. Vaccinia virus. In: Majer M., and Plotkin S.A. (Eds). "Strains of Human Viruses" (1972), S. Karger, Basel 125-241